1. A tetradecapeptide capable of inhibiting the release of somatotropin by the anterior lobe of the pituitary gland; somatostatin has a short half-life; it also inhibits the release of insulin, glucagon, and gastrin. Used in the treatment of acromegaly, gigantism, and pancreatic tumors.
The information shown above for somatostatin is provided by Stedman's.
* Stedman's, part of Lippincott Williams & Wilkins, provide a comprehensive line of health-science publications for healthcare professionals and medical students.